HEB泻了# Stock
l*o
1 楼
如果这样，基本上就没戏了吧？？
An FDA advisory panel is scheduled on Thursday to review an application for
approval from Hemispherx Biopharma (HEB) for Ampligen, a drug to treat
chronic fatigue syndrome, or CFS. In briefing notes posted in advance of the
panel meeting, FDA staff said it "identified multiple concerns with the
efficacy analyses for the Ampligen program." The FDA also stated "safety
data raise concern regarding Ampligen and abdominal pain with or without
liver function test abnormalities," adding that "Overall, the Agency has
concerns regarding the reliability of the safety database for Ampligen,
based upon lack of appropriate documentation and reporting."
An FDA advisory panel is scheduled on Thursday to review an application for
approval from Hemispherx Biopharma (HEB) for Ampligen, a drug to treat
chronic fatigue syndrome, or CFS. In briefing notes posted in advance of the
panel meeting, FDA staff said it "identified multiple concerns with the
efficacy analyses for the Ampligen program." The FDA also stated "safety
data raise concern regarding Ampligen and abdominal pain with or without
liver function test abnormalities," adding that "Overall, the Agency has
concerns regarding the reliability of the safety database for Ampligen,
based upon lack of appropriate documentation and reporting."
